Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882477 | 0.96 | HRH3 (0.93) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15462284 | 0.96 | HRH3 (0.93) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5665906 | 0.96 | HRH3 (0.93) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15762056 | 0.96 | HRH3 (0.93) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9371058 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15933346 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL557955 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3156252 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9126300 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9370421 | 0.93 | HRH3 (1.00) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| EP-3161029-B1 | PYRROLIDINE-BASED CATALYSTS FOR USE IN POLYURETHANE MATERIALS | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-01-11 | — | — | EP | claimed |
| US-11306008-B2 | Working medium and water treatment system | KABUSHIKI KAISHA TOSHIBA (JP) | 2022-04-19 | — | — | US | claimed |
| US-20210292194-A1 | WORKING MEDIUM AND WATER TREATMENT SYSTEM | KABUSHIKI KAISHA TOSHIBA (JP) | 2021-09-23 | — | — | US | claimed |
| CN-106164117-B | Pyrrolidine catalysts for polyurethane materials | 亨斯迈石油化学有限责任公司 | 2020-01-17 | — | — | CN | claimed |
| US-9988483-B2 | Pyrrolidine-based catalysts for use in polyurethane materials | HUNTSMAN PETROCHEMICAL LLC (US) | 2018-06-05 | — | — | US | claimed |
| EP-3161029-A1 | PYRROLIDINE-BASED CATALYSTS FOR USE IN POLYURETHANE MATERIALS | Huntsman Petrochemical LLC (US) | 2017-05-03 | — | — | EP | claimed |
| US-20170101501-A1 | PYRROLIDINE-BASED CATALYSTS FOR USE IN POLYURETHANE MATERIALS | HUNTSMAN PETROCHEMICAL LLC | 2017-04-13 | — | — | US | claimed |
| WO-2015200408-A1 | PYRROLIDINE-BASED CATALYSTS FOR USE IN POLYURETHANE MATERIALS | HUNTSMAN PETROCHEMICAL LLC (US) | 2015-12-30 | — | — | WO | claimed |
| US-20250084045-A1 | PROCESS FOR THE PRODUCTION OF BIS(PYRROLIDINO)BUTANE IN THE LIQUID PHASE | BASF SE (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4412992-A1 | PROCESS FOR THE PRODUCTION OF BIS(PYRROLIDINO)BUTANE IN THE LIQUID PHASE | BASF SE (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240208893-A1 | CONTINUOUS PROCESS FOR THE PRODUCTION OF AMINES IN THE GAS PHASE USING A RECYCLE GAS MODE | BASF SE (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208893-A1 | CONTINUOUS PROCESS FOR THE PRODUCTION OF AMINES IN THE GAS PHASE USING A RECYCLE GAS MODE | BASF SE (DE) | 2024-06-27 | — | — | US | disclosed |
| CN-118076590-A | Method for producing bis (pyrrolidinyl) butane in liquid phase | 巴斯夫欧洲公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20140018547-A1 | Process for Preparing Pyrrolidine | BASF SE (DE) | 2014-01-16 | — | — | US | disclosed |
| WO-2014009292-A1 | METHOD FOR PRODUCING PYROLLIDINE | BASF SE (DE) | 2014-01-16 | — | — | WO | disclosed |
| EP-1108715-B1 | Process for dehydration and purification of crude pyrrolidine | BASF AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-6353118-B1 | ONE STEP CONTINUOUS DISTILLATION AT A PRESSURE AT THE TOP OF LESS THAN 950 HPA IN A COLUMN HAVING A STRIPPING SECTION AND A RECTIFYING SECTION | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| EP-1108715-A1 | Process for dehydration and purification of crude pyrrolidine | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-20 | — | — | EP | disclosed |
| WO-1981001845-A1 | PROTON-CATALYSED REACTIONS IN WHICH WATER IS NOT A STOICHIOMETRIC REACTANT CATALYSED BY METAL CATION-EXCHANGED LAYERED CLAYS | BRITISH PETROLEUM CO (GB) | 1981-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084045-A1 | PROCESS FOR THE PRODUCTION OF BIS(PYRROLIDINO)BUTANE IN THE LIQUID PHASE | BBOX1, PPOX, POLB | HRH3 1342/4885MAPT 1233/4885CYP1A2 519/4885 |
| US-20140018547-A1 | Process for Preparing Pyrrolidine | SCO2, BBOX1, HMOX2 | HRH3 577/4885MAPT 2349/4885CYP1A2 332/4885 |
| US-20240208893-A1 | CONTINUOUS PROCESS FOR THE PRODUCTION OF AMINES IN THE GAS PHASE USING A RECYCLE GAS MODE | ADH1A, ADH1C, ADH5 | HRH3 20/4885MAPT 1584/4885CYP1A2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.